Clinical trials: Pharynx Carcinoma
Nasopharyngeal Carcinoma by AJCC V8 Stage
Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
The goal of this study is to learn the efficacy and safety of nimotuzumab combined with toripalimab and gemcitabine/cisplatin regimen treatment recurrent/distant-metastasis nasopharyngeal carcinoma.
- Trial name
- NCT06509009
- Testing
- Nimotuzumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Nutrition Disorders, Quality of Life
Early Use of Opioid in Radiation Mucositis
This study is a superiority research to evaluate the safety and effectiveness of early use of oxycodone control release tablet for radiation mucositis in nasopharyngeal carcinoma patients.
- Trial name
- NCT02309437
- Testing
- Oxycodone
- Where
- 4 sites in China
- Volunteers
- 200 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Nasopharyngeal Cancer, Epstein Barr Virus Infections
A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma
This clinical study is looking at a vaccine called MVA-EBNA1/LMP2. This is a new vaccine that has already been studied in small number of cancer patients.
- Trial name
- NCT01800071
- Testing
- MVA-EBNA1/LMP2 vaccine
- Where
- 5 sites in United Kingdom
- Volunteers
- 22 people
- Sponsor
- Cancer Research UK
Nasopharyngeal Neoplasms
Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma
Primary objective: To evaluate the response rate of biweekly gemcitabine and oxaliplatin (the GEMOX regimen) in the first line treatment of metastatic or recurrent nasopharyngeal carcinoma.
- Trial name
- NCT00436800
- Testing
- Gemcitabine, Oxaliplatin
- Where
- Hong Kong
- Volunteers
- 41 people
- Sponsor
- Sanofi
Nasopharyngeal Carcinoma
Hypoxia Imaging -Guided Radiotherapy of Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) differs from other head and neck malignancies in terms of its epidemiology, pathology, and treatment outcome . It is endemic in China and is one of the major public health problems.
- Trial name
- NCT02089204
- Testing
- FMISO-PET/CT, FDG-PET/CT, contrast-enhanced CT
- Volunteers
- 300 people
- Sponsor
- Xuzhou Medical University
Nasopharyngeal Carcinoma
Retrospective Study About Nasopharyngeal Carcinoma at C. S. Parc Tauli
Retrospective study of patients diagnosed with a nasopharyngeal carcinoma included in our data base care between June 1990 and September 2013.
- Trial name
- NCT02199132
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Corporacion Parc Tauli
Nasopharyngeal Carcinoma
Combining MRI and CEUS to Diagnose Small Cervical Lymph Node Metastases in NPC Patients
This is a single-center diagnostic accuracy study, with the purpose to define the criteria to diagnose small cervical lymph node metastases in patients with nasopharyngeal carcinoma by combining MRI scanning and contrast-enhanced…
- Trial name
- NPC-LN (NCT05389306)
- Testing
- MRI Scanning, Contrast-Enhanced Ultrasonography, Ultrasound-guided Lymph Node Aspiration
- Where
- China
- Volunteers
- 348 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC)
Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity
This is a an open-label, non-inferiority, multicenter, randomized phase III trial aimed to explore the efficacy and safety of shrinking the anterior border of CTV2 in nasopharyngeal carcinoma patients without tumor invasion into…
- Trial name
- NCT07072000
- Testing
- standard CTV delineation, reduced CTV delineation
- Where
- 5 sites in China
- Volunteers
- 550 people
- Sponsor
- Hai-Qiang Mai,MD,PhD
Effects of Chemotherapy, Stage IVC Nasopharyngeal Carcinoma
Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma
The investigators designed this study to evaluate the efficiency and the acute toxicities of recombinant human endostatin (endostar) combined with chemotherapy in the metastatic nasopharyngeal carcinoma (NPC).
- Trial name
- NCT01915134
- Testing
- Recombinant Human Endostatin plus gemcitabine and cisplatin, Gemcitabine and cisplatin
- Where
- China
- Volunteers
- 362 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma, Radiation Therapy Induced Change
Application of Whole-course Standardized Nutrition Management During Peri-radiotherapy in Patients With Nasopharyngeal Carcinoma After Radiotherapy: a Multicenter Randomized Controlled Clinical Study
This study will present an advanced equipment of tumor nutrition diagnosis and assesment for nasopharyngeal cancer(NPC) radiotherapy patients in nutritional risk screening, evaluation, diagnosis and directing nutritional…
- Conditions
- Nasopharyngeal Carcinoma, Radiation Therapy Induced Change, Nutrition Disorders
- Trial name
- NCT05008471
- Testing
- Formula nutrition
- Where
- China
- Volunteers
- 388 people
- Sponsor
- Sun Yat-sen University
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown Primary
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
This phase II trial tests how well lovastatin and pembrolizumab work in treating patients with head and neck cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started…
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown Primary, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma
- Trial name
- NCT06636734
- Testing
- Biospecimen Collection, Computed Tomography, Lovastatin
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Emory University
Nasopharyngeal Carcinoma (NPC)
Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma
The goal of this study is to investigate the outcomes of patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) or recurrent-metastatic nasopharyngeal carcinoma (RM-NPC) treated with a combination of immune…
- Trial name
- NCT06676293
- Testing
- Anti-PD1, asparaginase
- Where
- Taiwan
- Volunteers
- 8 people
- Sponsor
- Chang Gung Memorial Hospital
Nasopharyngeal Carcinoma
Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.
This is an open-label, single center, non-randomized, phase I trial to evaluate the safety and efficacy of gemcitabine combined with apatinib and toripalimab in patients with the recurrent or metastatic nasopharyngeal carcinoma.
- Trial name
- NCT04073784
- Testing
- Gemcitabine combined with Aptinib and Toripalimab
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Sun Yat-sen University
Glottic Carcinoma, Supraglottic Carcinoma
Clinical Treatments in Specialized Diseases of Laryngeal Carcinoma (LC) and Hypopharyngeal Carcinoma (HPC)
For early stage laryngeal carcinoma and hypohparyngeal carcinoma (T1 and T2), transoral laser microsurgery, open partial laryngectomy, radiotherapy, and transoral robotic surgery were performed according to NCCN guidelines…
- Conditions
- Glottic Carcinoma, Supraglottic Carcinoma, Subglottic Carcinoma, Pyriform Sinus Carcinoma
- Trial name
- NCT04908696
- Testing
- routines
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Nasopharyngeal Carcinoma, Toripalimab
Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial
This is a prospective, single-arm, phase II trial to study the efficacy of PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy in treating patients with locoregionally recurrent nasopharyngeal carcinoma.
- Conditions
- Nasopharyngeal Carcinoma, Toripalimab, Recurrent Nasopharyngeal Squamous Cell Carcinoma
- Trial name
- NCT04992988
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Hospital of Guangxi Medical University
Head and Neck Squamous Cell Carcinoma
BH4 in the Prevention and Treatment of Radiation-induced Skin Reactions for Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)
Head and neck squamous cell carcinoma (include nasopharyngeal carcinoma) is one of the most common malignant tumor in China, and radiotherapy is the main treatment method.
- Trial name
- NCT05299203
- Testing
- Sapropterin dihydrochloride tablets
- Volunteers
- 18 people
- Sponsor
- West China Hospital
Nasopharyngeal Carcinoma
18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma
The purpose of this study is to explore whether 18F-FDG PET/CT guided reduced-dose radiotherapy would maintain survival outcomes in nasopharyngeal carcinoma (NPC) patients.
- Trial name
- NCT04813705
- Testing
- Reduced dose, Conventional dose, Chemotherapy
- Where
- 4 sites in China
- Volunteers
- 93 people
- Sponsor
- Taizhou Hospital
Nasopharyngeal Carcinoma
Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to compare induction chemotherapy (TPF or GP) plus radiotherapy alone with induction chemotherapy plus concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma…
- Trial name
- NCT04414566
- Testing
- gemcitabine and cisplatin; docetaxel, cisplatin and fluorouracil, IMRT, IMRT and concurrent cisplatin
- Where
- China
- Volunteers
- 562 people
- Sponsor
- West China Hospital
Nasopharyngeal Carcinoma
Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy
This is an open, multicenter phase Ⅱ clinical trial on cetuximab (C225) combined with IMRT + concurrent chemotherapy of cisplatin in locoregionally advanced nasopharyngeal carcinoma.
- Trial name
- ENCORE (NCT00700440)
- Testing
- C225 (cetuximab)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancer
A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer
This study will evaluate the efficacy, safety, tolerability, and effect on quality of life of oral capecitabine in combination with intravenous (IV) cisplatin in participants with metastatic nasopharyngeal cancer.
- Trial name
- NCT02608073
- Testing
- Capecitabine, Cisplatin
- Where
- 9 sites in Hong Kong, Indonesia and 3 more
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.